Dr. Robert Schilling appointed as new CFO and Member of the Executive Board of RAUMEDIC AG
The Supervisory Board of RAUMEDIC AG, a leading global provider of polymer-based product solutions for the medical and pharmaceutical industries, has appointed Dr. Robert Schilling as Chief Financial Officer (CFO) and member of the Executive Board, effective October 1, 2023. Schilling succeeds Daniel Seibert, who is leaving the company at his own request after almost five years.
Mr. Schilling has extensive expertise in finance and controlling, which he has demonstrated in his career in various industries - most recently at Gerresheimer AG as Global Vice President Finance & Controlling in the Medical Systems Division.
Juergen Werner, Chairman of the Supervisory Board of RAUMEDIC AG, explains the decision in favor of Schilling: "It was particularly important to us to have a seamless transition in the financial management in order to ensure the company’s stability, flexibility and capability to act. In the Finance Department, all crucial information relevant for the management of the company are condensed. This makes the department essential - and the competent management of the department crucial."
In addition, according to Mr. Werner, a decisive criterion was "that a CFO not only successfully manages financial strategy processes, but also contributes important strategic suggestions and impulses for general corporate planning and company development on the Executive Board." Accordingly, the Chairman of the Supervisory Board is pleased "that Mr. Schilling, with his sound specialist knowledge, his many years of experience as well as proven achievements in his career, is now joining the company to provide decisive impulses at RAUMEDIC."
Stefan Seuferling, CEO and Chairman of the Executive Board of RAUMEDIC AG, is pleased to welcome Mr. Schilling, a proven Finance & Controlling expert with extensive industry knowledge. "I am very pleased to welcome Dr. Robert Schilling to the Executive Board of RAUMEDIC AG. His experience in the development of financial organizations, his expertise in financial planning and digitalization, and his industry experience around contract manufacturing of medical technology products make him an ideal appointment. We are confident that he will make a decisive contribution to shaping RAUMEDIC's growth," says Mr. Seuferling.
Mr. Seuferling also praises Mr. Daniel Seibert’s important contributions to the development of RAUMEDIC as predecessor of Mr. Schilling: "I would like to thank Daniel Seibert once again for his service, which made a decisive contribution to the overall development of the company during a period of dynamic growth. We wish Daniel Seibert all the best for his private and professional future."
RAUMEDIC wishes Mr. Schilling all the best in his new role and looks forward to a productive and successful collaboration.
RAUMEDIC develops solutions for life. Together with its customers, the medical technology company breaks new ground to improve the diagnosis and therapy of diseases. In doing so, RAUMEDIC focuses on polymer-based solutions for medical and pharmaceutical applications as well as products for intensive care. RAUMEDIC is represented worldwide and employs around 1,200 people at five production sites. In the core markets of Europe and North America, the company manufactures in its own clean room manufacturing facilities.